171096-33-6

Basic information

• Product Name: Methyl 2-(4,6-dichloropyriMidin-5-yl)acetate
• Synonyms: Methyl 2-(4,6-dichloropyriMidin-5-yl)acetate
• CAS NO: 171096-33-6
• Molecular Formula: C₇H₆Cl₂N₂O₂
• Molecular Weight: 221.04074
• Mol File: 171096-33-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 305.9±37.0 °C at 760 mmHg
• Flash Point: 138.8±26.5 °C
• Appearance: /
• Density: 1.4±0.1 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.41±0.50(Predicted)
• CAS DataBase Reference: Methyl 2-(4,6-dichloropyriMidin-5-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(4,6-dichloropyriMidin-5-yl)acetate(171096-33-6)
• EPA Substance Registry System: Methyl 2-(4,6-dichloropyriMidin-5-yl)acetate(171096-33-6)

Safety Data

• Hazardous Substances Data: 171096-33-6(Hazardous Substances Data)

Usage

General Description

Methyl 2-(4,6-dichloropyriMidin-5-yl)acetate is a chemical compound with the molecular formula C8H8Cl2N2O2. It is a derivative of pyrimidine, which is a heterocyclic organic compound. This chemical is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It has potential applications in the development of drugs for various medical conditions and as an ingredient in pesticides. Methyl 2-(4,6-dichloropyriMidin-5-yl)acetate is known for its ability to act as an inhibitor of specific enzymes and receptors, making it a valuable tool in drug discovery and development. It is important to handle this chemical with proper safety precautions and in accordance with regulations to minimize any potential hazards.

Upstream product

• 40967-67-7 trimethyl ethane-1,1,2-tricarboxylate 
• 7459-46-3 triethyl 1,1,2-ethanetricarboxylate 

Downstream Products

• 1402550-57-5 C₁₄H₁₂ClN₃O 
• 1369365-16-1 C₆H₆N₄O 
• 1402550-59-7 methyl 2-(4-amino-6-chloropyrimidin-5-yl)acetate 
• 1402550-60-0 C₆H₇ClN₄O 
• 1402550-61-1 isopropyl 2-(4-amino-6-chloropyrimidin-5-yl)acetate 
• 346599-63-1 4-chloro-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1226804-67-6 4-chloro-7-(2,4-dimethoxybenzyl)-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1226804-63-2 methyl 2-(4-chloro-6-(2,4-dimethoxybenzylamino)pyrimidin-5-yl)acetate 
• 853680-84-9 4-chloro-7-(4-methoxy-benzyl)-5-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 853680-76-9 4-chloro-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 853680-77-0 4-[7-(4-methoxy-benzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

1-(2-hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators

We present a novel series of selective androgen receptor modulators (SARMs) which shows excellent biological activity and physical properties. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitriles showed potent binding to the androgen receptor (AR) and activated AR-mediated transcription in vitro. Representative compounds demonstrated diminished activity in promoting the intramolecular interaction between the AR carboxyl (C) and amino (N) termini. This N/C-termini interaction is a biomarker assay for the undesired androgenic responses in vivo. In orchidectomized rats, daily administration of a lead compound from this series showed anabolic activity by increasing levator ani muscle weight. Importantly, minimal androgenic effects (increased tissue weights) were observed in the prostate and seminal vesicles, along with minimal repression of circulating luteinizing hormone (LH) levels and no change in the lipid and triglyceride levels. This lead compound completed a two week rat toxicology study, and was well tolerated at doses up to 100 mg/kg/day, the highest dose tested, for 14 consecutive days.

BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS

The present invention relates to Bicyclic Heterocycle Derivatives of Formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a diabetic

AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.